Notable concerns that warrant closer review
The company is pre-revenue, with minimal revenue generated from brine testing services and no secured future revenue streams.. Significant operating losses persist, with the company reliant on financing activities to fund operations and development.. Recent RSU grants to management are heavily performance-based, with significant portions tied to future stock exchange listing and market capitalization targets, indicating potential dilution or future compensation expenses.. Generated $0.03M in testing revenue in Q4 2025 vs. no revenue in Q4 2024.